JPRN-jRCT2080220038未知2 期
Dose-ranging study of OPC-41061 in patients with cardiac edema (congestive heart failure: CHF)
适应症
试验速览
- 阶段
- 2 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 79age old（—）
- 性别
- All
入选标准
- •CHF patients with edema, jugular venous distention, hepatomegaly, pulmonary congestion, or 3rd sound due to extracellular volume expansion despite taking oral furosemide, aged between 20 and 80 years, not inclusive, at time of consent
排除标准
- 未提供
研究者
相似试验
未知
2 期
A dose-defining study of OPC-41061 in treatment of hepatic edemaJPRN-jRCT2080220392Otsuka Pharmaceutical Co., Ltd.
未知
3 期
A clinical phamacological study of OPC-41061 in the treatment of cardiac edema (congestive heart failure)Cardiac edema (CHF)JPRN-jRCT2080220442Otsuka Pharmaceutical Co., Ltd.
未知
2 期
A long-term administration study of OPC-41061 in patients with autosomal dominant polycystic kidney disease (ADPKD) [Extension of study 156-04-001]Autosomal dominant polycystic kidney disease (ADPKD)JPRN-jRCT2080220665Otsuka Pharmaceutical Co., Ltd.17
未知
3 期
A long-term administration study of OPC-41061 in patients with autosomal dominant polycystic kidney disease (ADPKD) (2) [Extension of study 156-05-002]Autosomal dominant polycystic kidney disease (ADPKD)JPRN-jRCT2080220916Otsuka Pharmaceutical Co., Ltd.15
终止
2 期
A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative ColitisActive ulcerative colitisJPRN-jRCT2080220212Otsuka Pharmaceutical Co., Ltd.160